Phase1, STP7 Cocaine Drug-Drug Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions
Cocaine Use Disorder
Interventions
DRUG

STP7 (mavoglurant) or Placebo

"STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline."

Trial Locations (1)

66212

Altasciences Clinical Kansas, Overland Park

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Stalicla SA

INDUSTRY

NCT06273540 - Phase1, STP7 Cocaine Drug-Drug Interaction Study | Biotech Hunter | Biotech Hunter